Top in ID: Second COVID-19 shot; more cases in E. coli outbreak tied to McDonald's burgers

The CDC recommended that adults aged 65 years or older and anyone who is moderately or severely immunocompromised receive a second dose of 2024-2025 COVID-19 vaccine.

Additionally, the Advisory Committee on Immunization Practices recommended lowering the age for routine pneumococcal conjugate vaccination to 50 years.

The recommendations were made official after CDC Director Mandy K. Cohen, MD, MPH, signed off on them.

It was the top story in infectious disease last week.

In another top story, the CDC announced 26 more cases in the E coli outbreak linked to McDonald’s Quarter Pounders, bringing the total number of cases to 75.

They also announced that Michigan, New Mexico and Washington have been added to the list of states included in the outbreak, bringing the total to 13 states.

Read these and more top stories in infectious disease below:

CDC recommends 2nd COVID shot for some, lowering age for pneumococcal vaccination

A CDC advisory committee on recommended that adults aged 65 years or older and anyone who is at least moderately immunocompromised receive a second dose of COVID-19 vaccine this season. Read more.

CDC announces more cases, states in E. coli outbreak linked to McDonald’s burgers

The CDC announced 26 more cases in the multistate outbreak of Escherichia coli linked to McDonald’s Quarter Pounders, bringing the total to 75 cases in 13 states. Read more.

CDC: 1 dead in multistate E. coli outbreak linked to McDonald’s Quarter Pounders

One person has died and 10 have been hospitalized in a multistate outbreak of Escherichia coli infections linked to McDonald’s Quarter Pounders, the CDC said. Read more.

VIDEO: Paxlovid effective for people with prior immunity, study shows

Paxlovid reduced the risk for severe COVID-19 hospitalization or death among people with existing immunity from a previous infection or vaccination, according to pooled trial data presented at IDWeek. Watch here.

VIDEO: Lenacapavir shows ‘amazing’ results for resistant HIV

Lenacapavir, the twice-yearly injectable HIV drug, could potentially transform HIV prevention if it is approved as PrEP, research has shown. Watch here.